Compare Nasdaq Inc (NDAQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs TransMedics Group Inc — how do they compare? Nasdaq Inc trades at $93.65 (market cap $51.63B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Nasdaq Inc is far larger — about 18.8× TransMedics Group Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and TransMedics Group Inc for 24 Days on average.
| NDAQ | TMDX | |
|---|---|---|
Market Cap | $51.63B | $2.74B |
Volume | 2,668,175 | 949,331 |
Sector | Financials | Health |
52-Week High | $100.98 | $150.42 |
52-Week Low | $76.85 | $61.99 |
Typical Hold Time | 126 Days | 24 Days |
Enterprise Value | $58.09B | $3.13B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $93.65, up 1.87% on the day, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting further upside, while recent earnings beats and a 22.52% net income margin highlight robust profitability. Positive news includes the addition of Moderna to the Nasdaq-100 Index and HSBC adopting Nasdaq's Calypso platform, signaling business growth.
Outlook remains favorable with a consensus price target of $110.43, implying 18% upside. Key risks include cash flow volatility and high debt levels, but analyst sentiment is strongly bullish with 61% buy ratings. Revenue growth and AI-driven platform adoption present opportunities, though market volatility and competitive pressures warrant monitoring.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
